Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 08.06.2026 1 Ann Oncol 3 Br J Cancer 4 Cancer 2 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 3 Cancer Sci 1 Chest 1 Clin Cancer Res 3 Clin Lung Cancer 2 Eur J Cancer 1 Genes Chromosomes Cancer 1 Hum Pathol 3 Int J Cancer 1 J Cancer Res Clin Oncol 1 J Clin Oncol 1 J Natl Cancer Inst 1 J Nucl Med 2 J Thorac Cardiovasc Surg 1 J Thorac Oncol 1 JAMA Oncol 2 Lancet 1 Lancet Oncol 6 Lung Cancer 1 N Engl J Med 1 Nat Med 1 Oncogene 4 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. SHAW AT, Solomon BJ, Felip E, Bauer TM, et al
   Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
   Ann Oncol. 2026 May 29:S0923-7534(26)00876-8. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   

   
   Br J Cancer

2. HIGASHIYAMA RI, Yoshida T, Shiraishi K, Miyakoshi J, et al
   Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.
   Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03457.
   PubMed         Abstract available
   
   
3. MICHAEL A, Huynh J, Sutton K, Chow MC, et al
   The utility of electronic frailty index in cancer patients undergoing chemotherapy.
   Br J Cancer. 2026;134:1793-1800.
   PubMed         Abstract available
   
   
4. SUN S, Ma G, Cheng L, Zhang H, et al
   Novel transcription factor zinc finger 514 suppresses lung adenocarcinoma progression and enhances cisplatin sensitivity via transcriptional repression of COL1A1.
   Br J Cancer. 2026;134:1716-1729.
   PubMed         Abstract available
   
   

   
   Cancer

5. PARISI C, Barlesi F, Planchard D
   Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?
   Cancer. 2026;132 Suppl 1:e70422.
   PubMed         Abstract available
   
   
6. SETHAKORN N, Chiang AC
   The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer.
   Cancer. 2026;132 Suppl 1:e70418.
   PubMed         Abstract available
   
   
7. DONG C, Liu L, Qiao Y, Wang M, et al
   First-line envafolimab plus recombinant human-endostatin in advanced non-small cell lung cancer with PD-L1 tumor proportion score >/=1% (Endouble): A multicenter, prospective, single-arm, phase 2 trial.
   Cancer. 2026;132:e70479.
   PubMed         Abstract available
   
   
8. PASSIGLIA F, Passaro A, Gariazzo E, Montrone M, et al
   Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.
   Cancer. 2026;132:e70476.
   PubMed         Abstract available
   
   

   
   Cancer Epidemiol Biomarkers Prev

9. GORBATOV SD, Bittoni MA, Wu AH, Harper A, et al
   Dietary and Lifestyle Patterns Among Young Patients with Lung Cancer: Analysis of Mutation-Specific Phenotypes.
   Cancer Epidemiol Biomarkers Prev. 2026 Jun 3. doi: 10.1158/1055-9965.EPI-26-0057
   PubMed         Abstract available
   
   
10. MCGANN KC, Woodhouse P, Chen H, Kammer MN, et al
    Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    

    
    Cancer Lett

11. WANG Y, Zheng J, Zhang K, Mo W, et al
    Single-cell analysis reveals IL1B(+) macrophages promote lung metastasis in adenoid cystic carcinoma.
    Cancer Lett. 2026;653:218590.
    PubMed         Abstract available
    
    

    
    Cancer Sci

12. TANAKA T, Fujitani M, Taoka M, Shimomura I, et al
    Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model.
    Cancer Sci. 2026 Jun 1. doi: 10.1111/cas.70431.
    PubMed         Abstract available
    
    
13. NAGANO Y, Yokouchi H, Saito R, Honjo O, et al
    Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.
    Cancer Sci. 2026 May 31. doi: 10.1111/cas.70400.
    PubMed         Abstract available
    
    
14. KUMEDA H, Hirabayashi K, Mishima S, Morita K, et al
    Bispecific Ligand-Based EphB4 CAR-T Cells Generated Using Ephrin-B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma.
    Cancer Sci. 2026;117:1724-1735.
    PubMed         Abstract available
    
    

    
    Chest

15. REVEL MP, Goo JM, Vliegenthart R, Silva M, et al
    Smoking-Related Comorbidities Detected Through Low-dose CT Lung Cancer Screening: Current Evidence and Future Directions.
    Chest. 2026 May 29:S0012-3692(26)00761-0. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

16. FUKUMURA K, Jiang P, Yeboa DN, Singareeka Raghavendra A, et al
    Ionizing radiation enhances prognostically significant cellular immunity programs in the brain metastasis microenvironment.
    Clin Cancer Res. 2026 Mar 12. doi: 10.1158/1078-0432.CCR-25-3525.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

17. JUANG YR, Chen W, Ng AJH, Sim X, et al
    Development and Validation of Lung Cancer Risk Prediction Models in the Singapore Chinese Population.
    Clin Lung Cancer. 2026 May 2:S1525-7304(26)00066.
    PubMed         Abstract available
    
    
18. KILPATRICK M, Gundersen P, O'Reilly K, Goyal S, et al
    Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:11-18.
    PubMed         Abstract available
    
    
19. MARKOWITZ SB, Liu B, Miller A, Taoli E, et al
    High Adherence Over a Decade of Annual Lung Cancer Screening in an Occupational Cohort.
    Clin Lung Cancer. 2026;27:1-10.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

20. CORRE R, Monnet I, Moreau L, Pinsolle J, et al
    Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.
    Eur J Cancer. 2026;243:116845.
    PubMed         Abstract available
    
    
21. KANHAILAL AC, Knikman JE, Zielhuis SWJ, Kodach LL, et al
    The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.
    Eur J Cancer. 2026;241:116782.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

22. MASAGO K, Seto K, Sasaki E, Fujita Y, et al
    Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Genes Chromosomes Cancer. 2026;65:e70146.
    PubMed         Abstract available
    
    

    
    Hum Pathol

23. GAGNON MF, Rozenova K, Lu C, Sosa C, et al
    Gene expression and immunohistochemical phenotypes of high-grade epithelioid mesothelioma.
    Hum Pathol. 2026;173:106118.
    PubMed         Abstract available
    
    

    
    Int J Cancer

24. CECERE N, Alikhanyan K, Ernst C, Hafele L, et al
    Lung Cancer Patients Display Increased Expression of Bovine Meat and Milk Factor (BMMF) Proteins in Peritumor Alveolar Macrophages.
    Int J Cancer. 2026 Jun 1. doi: 10.1002/ijc.70574.
    PubMed         Abstract available
    
    
25. WANG S, Yu J
    Lipid Metabolic Reprogramming in Lung Cancer: Mechanisms and Therapeutic Targets in the Tumor Microenvironment.
    Int J Cancer. 2026 Jun 2. doi: 10.1002/ijc.70575.
    PubMed         Abstract available
    
    
26. HUANG M, Yang J, Peng P, Wang Y, et al
    Landscape of Chinese Lung Cancer Patients With Compound Mutations and Acquired Resistance Alterations: A Retrospective Study.
    Int J Cancer. 2026 Jun 3. doi: 10.1002/ijc.70545.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

27. ERNST P, Rachow T, Henn S, Hammersen JF, et al
    Residential radon exposure and lung cancer histology and stage: a population-based ecological study in Central Germany.
    J Cancer Res Clin Oncol. 2026;152:115.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

28. DOROSHOW DB, Leal TA, Waqar SN, Borghaei H, et al
    Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
    J Clin Oncol. 2026 Jun 3:JCO2501896. doi: 10.1200/JCO-25-01896.
    PubMed        
    
    

    
    J Natl Cancer Inst

29. POTTER AL, Kothagundla S, Guo Q, Cheney B, et al
    Millions of adults undergoing breast and colorectal cancer screening are eligible for lung cancer screening, but do not get screened.
    J Natl Cancer Inst. 2026 Jun 5:djag176. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

30. HOANG TT, Bauer D, Ingham A, Miranda IC, et al
    Delta-like Ligand 3-Directed (225)Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.
    J Nucl Med. 2026 Mar 26:jnumed.125.271302. doi: 10.2967/jnumed.125.271302.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

31. WANG A, Li K
    Natural killer cell-based stratification in resectable non-small cell lung cancer: For whom?
    J Thorac Cardiovasc Surg. 2026 May 30:S0022-5223(26)00977.
    PubMed        
    
    
32. ZHANG F, Han S, Song W
    Rethinking the surgical advantage after induction immunochemotherapy for non-small cell lung cancer: Is the benefit of local control histology-universal?
    J Thorac Cardiovasc Surg. 2026 Jun 4:S0022-5223(26)00979.
    PubMed        
    
    

    
    J Thorac Oncol

33. DACIC S, Shenker D, Redman M, Brunner L, et al
    Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy - IASLC MPR Project.
    J Thorac Oncol. 2026 Jun 1:103953. doi: 10.1016/j.jtho.2026.103953.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

34. LIU J, Han L, Wu L, Chen J, et al
    First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2026 Jun 4. doi: 10.1001/jamaoncol.2026.1645.
    PubMed         Abstract available
    
    

    
    Lancet

35. LU S, Liu B, Luo Y, Sun L, et al
    Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
    Lancet. 2026 May 31:S0140-6736(26)00966-9. doi: 10.1016/S0140-6736(26)00966.
    PubMed         Abstract available
    
    
36. CASCONE T, Mountzios G
    Ivonescimab in advanced squamous non-small-cell lung cancer: can we raise the survival bar?
    Lancet. 2026 May 31:S0140-6736(26)01026-3. doi: 10.1016/S0140-6736(26)01026.
    PubMed        
    
    

    
    Lancet Oncol

37. BALTACI E, Loges S, Mavila AD, Hoe C, et al
    Embedding equity in Germany's National Lung Cancer Screening roll-out: a call to action.
    Lancet Oncol. 2026;27:669-672.
    PubMed        
    
    

    
    Lung Cancer

38. ZHANG JT, Lin BX, Zhao XG, Zhong WZ, et al
    Circulating tumor DNA analysis in lung cancer: from molecular origins to analytical boundaries.
    Lung Cancer. 2026;217:109473.
    PubMed         Abstract available
    
    
39. OSPINA-SERRANO AV, Cobo M, Calvo V, Cantero A, et al
    Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence.
    Lung Cancer. 2026;217:109472.
    PubMed         Abstract available
    
    
40. KARIM N, Arnold K, Summers Y, Akram T, et al
    Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England.
    Lung Cancer. 2026;217:109469.
    PubMed         Abstract available
    
    
41. LIU WH, Cheng YJ, Kang J, Chen J, et al
    Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis.
    Lung Cancer. 2026;217:109413.
    PubMed         Abstract available
    
    
42. WANG J, Takundwa R, Yang H, Chai X, et al
    Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis.
    Lung Cancer. 2026;217:109465.
    PubMed         Abstract available
    
    
43. IKEDA S, Kenmotsu H, Koto R, Hirai T, et al
    Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab.
    Lung Cancer. 2026;218:109470.
    PubMed         Abstract available
    
    

    
    N Engl J Med

44. WU YL, Hochmair M, Yang Y, Yang XN, et al
    Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2602628.
    PubMed         Abstract available
    
    

    
    Nat Med

45. BYERS LA, Cho BC, Cooper AJ, Chiang AC, et al
    SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
    Nat Med. 2026 Jun 1. doi: 10.1038/s41591-026-04452.
    PubMed         Abstract available
    
    

    
    Oncogene

46. JIN Y, Tian X, Liu W, Guo B, et al
    Noncoding SNP rs17728461 modulates lung cancer progression via interchromosomal regulation of RAB27A expression.
    Oncogene. 2026 Jun 2. doi: 10.1038/s41388-026-03834.
    PubMed         Abstract available
    
    

    
    PLoS One

47. REDDINGTON H, Emmerick I, Diaz Collante J, Maini A, et al
    Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer.
    PLoS One. 2026;21:e0349231.
    PubMed         Abstract available
    
    
48. ASIM N, Sirshar M, Khan MZ, Ejaz S, et al
    Tensor enhanced chest cancer classification via CNN and Vision Transformer models.
    PLoS One. 2026;21:e0348863.
    PubMed         Abstract available
    
    
49. GARJANI H, Dubbeldam J, Stankova K, Brown JS, et al
    Which evolutionary game-theoretic model best captures NSCLC dynamics?
    PLoS One. 2026;21:e0347657.
    PubMed         Abstract available
    
    
50. 
    Correction: Expression of Concern: Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase.
    PLoS One. 2026;21:e0350591.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum